BennuBio has assumed control of an existing UNM licence for cytometer technology, securing commitments from three investors to target a commercial release by next year.

University of Queensland revealed it has generated more than 100 spinouts since 1988, with probiotic drink manufacturer Perkii becoming number 100 in 2016.

Twentyeight-Seven Therapeutics has officially launched with $65m in series A funding to commercialise oncology treatments based on research at Harvard Medical School.

Novartis Venture Fund, a founding investor, co-led a $65m series A round to launch cancer treatment developer Twentyeight-Seven Therapeutics.

Guardant Health is targeting $100m in proceeds for its initial public offering on the Nasdaq Global Select Market, which would offer an exit to SoftBank.

Boston Scientific will pay $500m upfront and up to $100m in milestone payments to acquire Augmenix, providing exits to Varian Medical Systems and Ascension Health.

Medison Ventures was among the participants in a round that will fund clinical tests for Alpha Tau's radiation-based cancer treatment.

Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline, based on research from Duke University.

The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.